Shares of The Medicines Co. (NASDAQ:MDCO) were up 3.9% on Thursday . The company traded as high as $38.37 and last traded at $38.33, with a volume of 448,505 shares. The stock had previously closed at $36.90.

A number of analysts have weighed in on MDCO shares. Cowen and Company reissued a “buy” rating on shares of The Medicines in a report on Tuesday, May 10th. Jefferies Group reaffirmed a “buy” rating and issued a $44.00 target price on shares of The Medicines in a report on Friday, May 6th. Leerink Swann reaffirmed a “buy” rating and issued a $53.00 target price on shares of The Medicines in a report on Thursday, June 23rd. Chardan Capital reaffirmed a “buy” rating on shares of The Medicines in a report on Thursday, June 2nd. Finally, Guggenheim lifted their target price on shares of The Medicines from $45.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, July 27th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $47.33.

The stock’s market cap is $2.64 billion. The firm’s 50-day moving average price is $36.64 and its 200-day moving average price is $34.63.

The Medicines (NASDAQ:MDCO) last released its earnings results on Wednesday, July 27th. The company reported ($0.62) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.54. During the same quarter last year, the company posted ($0.65) earnings per share. The business had revenue of $54.70 million for the quarter, compared to analysts’ expectations of $41.93 million. The business’s quarterly revenue was down 26.5% compared to the same quarter last year. Equities research analysts anticipate that The Medicines Co. will post ($1.36) earnings per share for the current year.

In other news, Director Hiroaki Shigeta sold 3,849 shares of the stock in a transaction that occurred on Monday, July 11th. The stock was sold at an average price of $38.50, for a total transaction of $148,186.50. Following the completion of the transaction, the director now directly owns 23,547 shares in the company, valued at approximately $906,559.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Melvin K. Spigelman sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $37.00, for a total value of $555,000.00. Following the sale, the director now directly owns 53,970 shares in the company, valued at $1,996,890. The disclosure for this sale can be found here.

Several large investors have recently bought and sold shares of the stock. RS Investment Management Co. LLC raised its stake in The Medicines by 76.1% in the fourth quarter. RS Investment Management Co. LLC now owns 1,198,632 shares of the company’s stock valued at $44,757,000 after buying an additional 517,940 shares in the last quarter. Marshall Wace LLP purchased a new stake in The Medicines during the fourth quarter valued at about $4,677,000. Dimensional Fund Advisors LP raised its stake in The Medicines by 5.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,895,993 shares of the company’s stock valued at $70,796,000 after buying an additional 105,865 shares in the last quarter. Bank of Montreal Can raised its stake in The Medicines by 29.4% in the fourth quarter. Bank of Montreal Can now owns 297,492 shares of the company’s stock valued at $11,108,000 after buying an additional 67,616 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in The Medicines by 8.5% in the fourth quarter. Principal Financial Group Inc. now owns 468,857 shares of the company’s stock valued at $17,507,000 after buying an additional 36,761 shares in the last quarter.

The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.